Evidence map›Paper›PMID 36152282›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Fast Protocols for Characterizing Antibody-Peptide Binding.

Sophie Cleaver, Matthew Gardner, Anthony Barlow, Enrico Ferrari, Mikhail Soloviev

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sophie CleaverDepartment of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Matthew GardnerDepartment of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Anthony BarlowDepartment of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
Enrico FerrariSchool of Life Sciences, University of Lincoln, Lincoln, UK.
Mikhail SolovievDepartment of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK. mikhail.soloviev@rhul.ac.uk.
Royal Holloway University of London · GBUniversity of Lincoln · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microarray assay formats gained popularity in the 1990s, first implemented in DNA-based arrays but later adopted for use with proteins, namely antibodies, peptides, low molecular weight (LMW) molecules, such as lipids, and even tissues. In nucleic acid-based affinity assays and arrays, but not in protein or peptide arrays, the specificity and affinity of complementary strand interactions can be deduced from or adjusted through modifications to the nucleotide sequence. Arrays of LMW molecules are characterized by largely uniform but low binding affinities. Multiplexed protein-based affinity assays, such as microarrays, might present an additional challenge due to heterogeneity of antigen properties and of their binding affinities. The use of peptides instead of proteins reduces physical heterogeneity of these reagents through either the widened peptide selection options or rational sequence engineering. However, rational engineering of binding affinities remains an unmet need, and peptide-binding affinities to the respective antipeptide antibodies could vary by orders of magnitude. Hence, multiplexing of such assays by using a microarray format and data analysis and interpretation requires some knowledge of their binding affinities. Low-throughput binding assays to characterize such peptide-antipeptide antibodies interactions are widely available, but scaling-up of traditional protein- and peptide-binding assays might present practical challenges. Here, we describe fast label-free practical approach especially suitable for estimating peptide-binding affinities. The method in question relies on commercially available biolayer interferometry-based equipment with a protocol which can be easily scaled-up, subject to user needs and equipment availability.

Indexed as

AntibodiesNucleic AcidsDNALipidsPeptidesProtein BindingProteinsAntibodiesDNALipidsNucleic AcidsPeptidesProteinsAffinity assayAntibodyAntigenBindingBinding kineticsBiolayer interferometryLabel-free bindingLangmuir bindingPeptideProtein–protein interactionsSurface plasmon resonance

Identifiers

PMID36152282
OpenAlexW4296981917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.